Bicycle Therapeutics plc
BCYC
$4.01
-$0.18-4.19%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -29.09% | -98.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -29.09% | -98.15% | |||
| Cost of Revenue | -12.34% | 2.27% | |||
| Gross Profit | 12.02% | -2,359.39% | |||
| SG&A Expenses | -27.74% | -13.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.85% | -3.06% | |||
| Operating Income | 16.68% | -219.30% | |||
| Income Before Tax | 17.16% | -221.10% | |||
| Income Tax Expenses | -47.67% | -86.40% | |||
| Earnings from Continuing Operations | 17.25% | -201.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.25% | -201.80% | |||
| EBIT | 16.68% | -219.30% | |||
| EBITDA | 16.88% | -235.66% | |||
| EPS Basic | 17.39% | -200.38% | |||
| Normalized Basic EPS | 17.30% | -310.88% | |||
| EPS Diluted | 17.39% | -200.38% | |||
| Normalized Diluted EPS | 17.30% | -310.88% | |||
| Average Basic Shares Outstanding | 0.17% | 0.46% | |||
| Average Diluted Shares Outstanding | 0.17% | 0.46% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||